GLPG2737 single dose

DRUG2 trials

Sponsors

Galapagos NV

Conditions

Cystic FibrosisHealthy

Phase 1

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

CompletedNCT03410979

Galapagos NVHealthy

Start: 2016-11-25End: 2017-08-15Updated: 2018-01-25

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

CompletedNCT03450720

Galapagos NVCystic Fibrosis

Start: 2017-06-28End: 2017-08-16Updated: 2018-03-19